These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 7563929)

  • 21. Low dose alpha interferon therapy can be effective in chronic active hepatitis C. Results of a multicentre, randomised trial.
    Sánchez-Tapias JM; Forns X; Ampurdanés S; Titó L; Planas R; Viver JM; Acero D; Torres M; Mas P; Morillas R; Forné M; Espinós J; Llovet JM; Costa J; Olmedo E; López-Labrador FX; Jiménez de Anta MT; Rodés J
    Gut; 1996 Apr; 38(4):603-9. PubMed ID: 8707096
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Disappointing response of chronic C hepatitis to interferon].
    Theodor E; Regev A
    Harefuah; 1997 Mar; 132(6):402-3, 447. PubMed ID: 9153855
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Complete response to twice-a-day interferon-beta with standard interferon-alpha therapy in acute hepatitis C after a needle-stick.
    Oketani M; Higashi T; Yamasaki N; Shinmyozu K; Osame M; Arima T
    J Clin Gastroenterol; 1999 Jan; 28(1):49-51. PubMed ID: 9916668
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of combination therapy with interferon and azidothymidine in chronic type C hepatitis: a pilot study.
    Tsutsumi M; Takada A; Sawada M
    J Gastroenterol; 1995 Aug; 30(4):485-92. PubMed ID: 7550859
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term administration of natural interferon-alpha in patients with chronic hepatitis C: relationship to serum RNA concentration, HCV-RNA genotypes, histological changes and hepatitis C virus.
    Kumada T; Nakano S; Takeda I; Sugiyama K; Osada T; Kiriyama S; Toyoda H; Sasa T; Shibata M; Morishima T; Nakano I; Fukuda Y; Kosaka Y; Tameda Y; Nakashima M
    J Gastroenterol Hepatol; 1996 Feb; 11(2):159-65. PubMed ID: 8672762
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cryptosporidiosis in a patient on PEG-interferon and ribavirin for recurrent hepatitis C after living donor liver transplantation.
    Manz M; Steuerwald M
    Transpl Infect Dis; 2007 Mar; 9(1):60-1. PubMed ID: 17313476
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of hepatitis C-virus-reinfection after liver transplant with silibinin in nonresponders to pegylated interferon-based therapy.
    Eurich D; Bahra M; Berg T; Boas-Knoop S; Biermer M; Neuhaus R; Neuhaus P; Neumann U
    Exp Clin Transplant; 2011 Feb; 9(1):1-6. PubMed ID: 21605016
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Parameters predicting response to alpha-interferon treatment in chronic hepatitis C.
    Glück T; Seelig R; Dette S; Bühring HJ; Renz M; Kwon S; Wiedmann KH; Weber P
    Hepatogastroenterology; 1997; 44(14):484-91. PubMed ID: 9164523
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rapid growth of hepatocellular carcinoma after or during interferon treatment of chronic hepatitis C: report of three cases.
    Onitsuka A; Yamada N; Yasuda H; Miyata T; Kachi T
    Surg Today; 1996; 26(2):126-30. PubMed ID: 8919284
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interferon-ribavirin combination therapy for chronic hepatitis C.
    Schalm SW; Brouwer JT; Chemello L; Alberti A; Bellobuono A; Ideo G; Schwartz R; Weiland O
    Dig Dis Sci; 1996 Dec; 41(12 Suppl):131S-134S. PubMed ID: 9011471
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Vogt-Koyanagi-Harada disease associated with interferon-alpha and ribavirin therapy for chronic hepatitis C infection].
    Chebil A; Kort F; Bouraoui R; Youssef NB; El Matri L
    J Fr Ophtalmol; 2010 Mar; 33(3):185-8. PubMed ID: 20172621
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined interferon alpha2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial.
    Inoue K; Sekiyama K; Yamada M; Watanabe T; Yasuda H; Yoshiba M
    J Gastroenterol; 2003; 38(6):567-72. PubMed ID: 12825133
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Therapeutic strategies for hepatitis C].
    Tsubota A; Kumada H
    Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):441-7. PubMed ID: 15359839
    [No Abstract]   [Full Text] [Related]  

  • 34. Effectiveness of interferon-alpha therapy in chronic hepatitis C is associated with the amount of interferon-alpha receptor mRNA in the liver.
    Fukuda R; Ishimura N; Kushiyama Y; Moriyama N; Ishihara S; Nagasawa S; Miyake T; Niigaki M; Satoh S; Sakai S; Akagi S; Watanabe M; Fukumoto S
    J Hepatol; 1997 Mar; 26(3):455-61. PubMed ID: 9075649
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prolonged treatment (2 years) with different doses (3 versus 6 MU) of interferon alpha-2b for chronic hepatitis type C. Results of a multicenter randomized trial.
    Saracco G; Borghesio E; Mesina P; Solinas A; Spezia C; Macor F; Gallo V; Chiandussi L; Donada C; Donadon V; Spirito F; Mangia A; Andriulli A; Verme G; Rizzetto M
    J Hepatol; 1997 Jul; 27(1):56-62. PubMed ID: 9252074
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Extrahepatic manifestations of chronic viral hepatitis.
    Willson RA
    Am J Gastroenterol; 1997 Jan; 92(1):3-17. PubMed ID: 8995930
    [No Abstract]   [Full Text] [Related]  

  • 37. [Hepatitis B and C: current therapy].
    Bruch HR; Höhner U; Müller R
    Praxis (Bern 1994); 1998 Oct; 87(42):1408-12. PubMed ID: 9824948
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Guidelines for treatment of hepatitis C].
    Iino S
    Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):342-6. PubMed ID: 15359818
    [No Abstract]   [Full Text] [Related]  

  • 39. Comparison of treatment with two different doses of leukocyte interferon alpha in patients with chronic hepatitis C.
    Laghi V; Toccaceli F; Rosati S; Monini A; Grimaldi M; Foglianti G; Canova N; Palazzini E
    Hepatogastroenterology; 1997; 44(16):1182-6. PubMed ID: 9261621
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Epidemic outbreak of acute hepatitis C--clinical course, histology and effectiveness of therapy].
    Cianciara J; Jabłońska J; Horban A; Walewska-Zielecka B
    Przegl Epidemiol; 2005; 59(2):385-94. PubMed ID: 16190545
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.